Literature DB >> 8399290

Structural requirements for the inhibition of membrane fusion by carbobenzoxy-D-Phe-Phe-Gly.

R M Epand1, R F Epand, C D Richardson, P L Yeagle.   

Abstract

The peptide ZfFG is known to inhibit non-bilayer phase formation as well as vesicle-vesicle and viral fusion. In order to ascertain some of the properties or structural features of this peptide which were important for the inhibition of membrane fusion, the blocking group was transferred from the amino to the carboxyl end to make fFGOBz. The fFGOBz lowered the bilayer to hexagonal phase transition temperature of dielaidoylphosphatidylethanolamine and it promoted the formation of isotropic phases in monomethyldioleoylphosphatidylethanolamine. The promotion of non-bilayer phases by fFGOBz appeared to be enhanced by a charged terminal amino group as higher pH or formylation of the amino group both decreased the effectiveness of this peptide to induce formation of the hexagonal phase. With the monomethyldioleoylphosphatidylethanolamine, the fFGOBz also promoted vesicle leakage and fusion as measured by lipid intermixing. The fFGOBz did not inhibit the formation of lipid structures of high curvature, resulting from sonication of phosphatidylcholine, as did ZfFG. Thus, the effects of fFGOBz on membranes are in sharp contrast to those of ZfFG and more closely resemble the behaviour of larger fusion peptides corresponding to the amino-terminal segment of viral fusion proteins. Our results demonstrate that having the carbobenzoxy group on the amino-terminus of fFG is important for giving the peptide derivative the property of inhibiting membrane fusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399290     DOI: 10.1016/0005-2736(93)90239-v

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Cytosolic ATPases, p97 and NSF, are sufficient to mediate rapid membrane fusion.

Authors:  M Otter-Nilsson; R Hendriks; E I Pecheur-Huet; D Hoekstra; T Nilsson
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

2.  Measles virus glycoprotein complexes preassemble intracellularly and relax during transport to the cell surface in preparation for fusion.

Authors:  Melinda A Brindley; Sukanya Chaudhury; Richard K Plemper
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  The influenza fusion peptide adopts a flexible flat V conformation in membranes.

Authors:  Sébastien Légaré; Patrick Lagüe
Journal:  Biophys J       Date:  2012-05-15       Impact factor: 4.033

4.  15N NMR study of the ionization properties of the influenza virus fusion peptide in zwitterionic phospholipid dispersions.

Authors:  Z Zhou; J C Macosko; D W Hughes; B G Sayer; J Hawes; R M Epand
Journal:  Biophys J       Date:  2000-05       Impact factor: 4.033

5.  Peptidophospholipids: synthesis, phospholipase A2 catalyzed hydrolysis, and application to development of phospholipid prodrugs.

Authors:  Renato Rosseto; Joseph Hajdu
Journal:  Chem Phys Lipids       Date:  2014-06-04       Impact factor: 3.329

6.  The mechanism of lamellar-to-inverted hexagonal phase transitions in phosphatidylethanolamine: implications for membrane fusion mechanisms.

Authors:  D P Siegel; R M Epand
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

7.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

8.  Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol.

Authors:  Eve-Isabelle Pécheur; Dimitri Lavillette; Fanny Alcaras; Jennifer Molle; Yury S Boriskin; Michael Roberts; François-Loïc Cosset; Stephen J Polyak
Journal:  Biochemistry       Date:  2007-04-25       Impact factor: 3.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.